
The Indian pharmaceutical market (IPM) surged by 8.1% to reach ₹2,40,672 crore in fiscal year 2025, according to market intelligence firm Pharma Trac. The firm forecasts this strong growth trajectory to continue, projecting a similar 7.8-8.1% expansion rate for 2026. Sun Pharma emerged as the top performer in terms of domestic sales revenue for 2025, generating ₹20,255 crore. Other significant contributors included Abbott India (₹14,277 crore), Cipla (₹13,484 crore), Mankind Pharma (₹13,321 crore), and Alkem Laboratories (₹9,900 crore). These figures highlight the sustained strength of India's pharmaceutical sector.
Lupin Ltd., established in 1968 and listed on NSE as LUPIN and BSE as 500257, has achieved a new 52-week high in the past week, joining JB Chemicals & Pharmaceuticals Ltd. in reaching similar milestones. Both companies are classified by market analysts as "Strong Performer, Getting Expensive" - indicating strong quality and technical performance but with medium valuation concerns. Lupin is a global pharmaceutical company focused on developing and distributing a diverse range of healthcare products, including generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. JB Chemicals, incorporated in 1976, specializes in manufacturing and marketing pharmaceutical formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company's next board meeting is scheduled for January 16, 2026, for quarterly results announcement.
Sales of respiratory medicines, including anti-allergics and anti-asthma therapies, surged past ₹1,950 crore in December 2025, marking the highest monthly level ever recorded, according to data from market research firm Pharmarack. The December sales were 10% higher than the corresponding month in 2024 and over 18% more compared with 2023, indicating a consistent increase each year and signaling a troubling escalation in pollution-linked illnesses across cities.
For the October-December quarter, the period when pollution typically peaks, respiratory sales rose in tandem by 14% year-on-year over 2024 and by 8% over 2023, as reported by Pharmarack. During the quarter, respiratory therapy sales crossed ₹5,620 crore, a rise of 17% over the previous quarter. A majority under this therapy - nearly ₹3,500 crore - was contributed by anti-asthma and COPD (chronic obstructive pulmonary disease) medication. Looking ahead to 2026, the respiratory segment is expected to grow 8-9%, while cardiac treatments are projected to expand 11-12%, followed by anti-diabetic (10-11%) and neuro segments (9-10%).
Foracort, the medication used for asthma and respiratory issues, emerged among the top selling drugs during the winter months. In December, it was the second largest selling drug with sales of ₹90 crore, following weight-loss therapy Mounjaro. Other widely-used therapies during these months include Augmentin (marketed by GSK Pharma) and Paracetamol for pain and fever management. The anti-diabetic segment saw a remarkable 9.4% growth in 2025, largely propelled by a 127.9% surge in GLP-1 agonist drugs such as Eli Lilly's Mounjaro and Novo Nordisk's Ozempic.
Sheetal Sapale of Pharma Trac noted that the projected slight moderation in cardiac segment growth for 2026 is due to the expanding base of this segment. For diabetes therapies, while GLP-1 agonists experienced over 100% growth recently, a period of consolidation is anticipated due to the entry of branded generics, which may increase market volume but moderate value growth. Pharma Trac categorizes the IPM into four key segments: high-growth lifestyle and therapies, demography-driven therapies for an aging population, mature acute therapies, and OTC/OTX categories. The strong performance of individual stocks like Lupin and JB Chemicals achieving new highs demonstrates broad-based investor confidence in the sector's growth prospects.